Gabapentinoids Increase Hunger, Reduce Activity, and Alter Lipids
Gabapentin and pregabalin (gabapentinoids) are increasingly prescribed beyond their original anticonvulsant indication — for neuropathic pain, fibromyalgia, anxiety disorders, and insomnia. Their weight gain profile, once considered minor, has become clinically significant as prescriptions have increased 15-fold over the past decade. Research documents that gabapentin produces weight gain in 10-20% of users, while pregabalin (Lyrica) produces weight gain in 15-25% of users, with average gains of 2-5 kg in the first 6-12 months. The mechanism is distinct from other weight-promoting medications: gabapentinoids bind to alpha-2-delta subunits of voltage-gated calcium channels, modulating neurotransmitter release in ways that affect both central appetite regulation and peripheral metabolism.[1]
The appetite-stimulating mechanism of gabapentinoids involves GABA-mediated hypothalamic hunger signaling. By enhancing GABAergic transmission in the hypothalamus, gabapentinoids increase the activity of NPY/AgRP (appetite-stimulating) neurons while potentially suppressing POMC/CART (satiety) neurons. This produces a subtle but persistent increase in hunger that patients often describe as 'always wanting to eat more' or 'never feeling satisfied after meals.' The sedation that gabapentinoids commonly produce compounds the appetite effect: reduced physical activity (lower NEAT by 100-200 calories daily) combined with increased food intake creates a consistent caloric surplus. Research from Epilepsia documented that patients on gabapentin showed 15% increases in daily caloric intake combined with 20% reductions in physical activity — the combined effect producing the positive energy balance responsible for weight accumulation.
Research shows women prescribed gabapentin for fibromyalgia face a particular metabolic challenge because fibromyalgia itself is associated with metabolic disruption — HPA axis dysfunction, insulin resistance, inflammatory cytokine elevation, and sleep fragmentation — that gabapentin's weight-promoting effects compound. Research from the Journal of Pain Research documented that women with fibromyalgia already showed resting metabolic rates 8-12% below predicted values before medication, and gabapentin treatment produced an additional 5-8% metabolic suppression through sedation-mediated activity reduction. The woman with fibromyalgia who gains weight on gabapentin is experiencing the intersection of disease-mediated metabolic disruption and medication-mediated metabolic suppression — a dual burden that conventional dietary advice cannot adequately address.
Supporting metabolic health during gabapentinoid use requires counteracting the specific appetite, activity, and metabolic effects without interfering with the medication's therapeutic calcium channel modulation. Tulsi (Holy Basil) provides complementary anxiolytic and analgesic support through different mechanisms — potentially allowing lower gabapentin doses (under physician guidance) that produce less metabolic disruption. Tulsi's cortisol modulation addresses the HPA axis dysfunction common in fibromyalgia and chronic pain conditions. Tulsi's blood sugar-stabilizing effects counteract the glycemic volatility that increased carbohydrate intake from appetite stimulation produces. Green Tea EGCG provides AMPK-mediated metabolic activation that directly counteracts the sedation-mediated metabolic suppression — restoring fat oxidation capacity and thermogenesis through biochemical pathways rather than physical activity (which sedation impairs). EGCG's L-theanine provides calm alertness that partially offsets gabapentinoid sedation without counteracting the therapeutic mechanism. Oleuropein provides anti-inflammatory and insulin-sensitizing support. Cayenne capsaicin provides TRPV1-mediated appetite suppression and thermogenic activation — both operating through non-GABAergic pathways unaffected by gabapentinoid mechanisms. African Mango provides fiber-based mechanical satiety. The liquid formulation ensures absorption.
People with obesity consistently have less Turicibacter. The microbe may promote healthy weight in humans.
— Dr. June Round, University of Utah, 2025
What This Means For You
The data is published. The mechanism is confirmed. The compounds exist.
The only variable is whether you act on the science — or wait for your doctor to hear about it in 2042.